Safety outcomes of tocilizumab and tofacitinib treatment for rheumatoid arthritis: Target trial emulation
Tocilizumab and tofacitinib act along the same inflammatory pathway. A lower herpes zoster incident rate was observed in the tocilizumab group than in the tofacitinib group. The incidence rates of other safety concerns and mortality rates were comparable in both groups of patients with RA treated in real-world settings.
Authors
- Yao‐Fan Fang
- Chang‐Fu Kuo (ORCID: https://orcid.org/0000-0002-9770-5730)
- Shu‐Hao Chang (ORCID: https://orcid.org/0000-0002-3427-6035)
- Lai‐Chu See (ORCID: https://orcid.org/0000-0002-1379-8969)
Institutions
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1111/1756-185x.15406
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Chang Gung Memorial Hospital, Linkou